- Tytuł:
- Application of two lines of chemotherapy: gemcitabine with nab-paclitaxel and liposomal irinotecan with 5-fluorouracil and leucovorin in patient with advanced pancreatic adenocarcinoma
- Autorzy:
-
Ostrowska-Cichocka, Krystyna
Wojtukiewicz, Marek Z. - Powiązania:
- https://bibliotekanauki.pl/articles/2047219.pdf
- Data publikacji:
- 2021-07-11
- Wydawca:
- Medical Education
- Tematy:
-
advanced pancreatic cancer
gemcitabine in combination with nab-paclitaxel
liposomal - Opis:
- Pancreatic cancer is a disease with high mortality. It is predicted to become the second leading cause of cancer death in some regions of the world. Frequent diagnosis at an advanced stage contributes to 5-year survival at a highly unsatisfactory level of 2–9%. Due to the lack of early symptoms, nearly 80% of patients receive a diagnosis when distant metastases develop. So far, the most frequently used programs in the treatment of patients with pancreatic cancer in the stage of neoplastic spreading include: FOLFIRINOX (oxaliplatin, 5-fluorouracil, irinotecan, leucovorin), gemcitabine alone or in combination with nab-paclitaxel or erlotinib. Based on the results of the phase III study NAPOLI-1, liposomal irinotecan in combination with 5-fluorouracil (5-FU) and leucovorin (LV ) was approved as the first regimen for use in the second or subsequent line of therapy in patients with advanced pancreatic cancer previously treated with gemcitabine. This paper presents a case of a patient with advanced pancreatic cancer who was treated with two lines of chemotherapy – gemcitabine in combination with nab-paclitaxel and liposomal irinotecan with 5-FU/LV . The treatment was well tolerated and was considered a valuable therapeutic option. A 2-year overall survival was obtained from the diagnosis of the disease.
- Źródło:
-
OncoReview; 2021, 11, 3; 68-72
2450-6125 - Pojawia się w:
- OncoReview
- Dostawca treści:
- Biblioteka Nauki
Artykuł